Time filter

Source Type

Liu L.,First Peoples Hospital of Zhengzhou | Chen X.,Cancer Hospital of Henan Province | Gao M.,Zhengzhou University
Chinese Journal of Clinical Oncology

Objective: To investigate the response rate and adverse reactions in patients with advanced or metastatic gastric cancer treated with the regimen of Docetaxel in combination with Oxaliplatin and Capecitabine. Methods: Fifty-six patients were treated with the regimen as follows: Docetaxel 75mg/m2, intravenous, day 1; Oxaliplatin 85mg/m2, intravenous, day 2; Capecitabine 1000mg/m2, twice a day, PO, for 14 days, 21 days for each cycle. Evaluation was performed at the end of 2 cyeles. Results: All of these 56 patients were evaluable for response. Six (10.7%) patients achieved complete response (CR), 30 (53.6%) patients had partial response (PR), 12 (21.4%) patients had stable disease (SD), 8 (14.3%) patients had disease progression (DP), with a total response rate ( RR) of 64.3%. The median progression-free survival was 6.2 months (3.6-11.8 months) and the median overall survival time was 11.6 months (5.9-14.6 months). The most common adverse effects were myelosuppression, gastrointestinal toxicities and neurotoxicity. No chemotherapy-related death was observed. Conclusion: Docetaxel combined with Oxaliplatin and Capecitabine is effective for advanced gastric cancer, with tolerable side effects. Source

Wang X.,Peking Union Medical College | Niu H.,Peking Union Medical College | Fan Q.,Zhengzhou University | Lu P.,The First Affiliated Hospital of Xinxiang Medical College | And 9 more authors.

This study aimed to search for a molecular marker for targeted epithelial growth factor receptor (EGFR) inhibitor Icotinib by analyzing protein expression and amplification of EGFR proto-oncogene in esophageal squamous cell carcinoma (ESCC) patients. Immunohistochemistry and fluorescence in situ hybridization (FISH) was used to assess EGFR expression and gene amplification status in 193 patients with ESCC. We also examined the association between EGFR overexpression and the efficacy of a novel EGFR TKI, icotinib, in 62 ESCC patients. Of the 193 patients, 95 (49.2%) patients showed EGFR overexpression (3+), and 47(24.4%) patients harbored EGFR FISH positivity. EGFR overexpression was significantly correlated with clinical stage and lymph node metastasis (p<0.05). In addition, EGFR overexpression was significantly correlated with EGFR FISH positivity (p<0.001). Among the 62 patients who received icotinib, the response rate was 17.6% for patients with high EGFR-expressing tumors, which was markedly higher than the rate (0%) for patients with low to moderate EGFR-expressing tumors (p=0.341). Furthermore, all cases responded to icotinib showed EGFR overexpression. In conclusion, our study suggests that EGFR overexpression might potentially be used in predicting the efficacy in patients treated with Icotinib. These data have implications for both clinical trial design and therapeutic strategies. Source

Wu C.,Peking Union Medical College | Wang Z.,U.S. National Institutes of Health | Wang Z.,SAIC | Song X.,Xinxiang Medical University | And 165 more authors.
Nature Genetics

We conducted a joint (pooled) analysis of three genome-wide association studies (GWAS) of esophageal squamous cell carcinoma (ESCC) in individuals of Chinese ancestry (5,337 ESCC cases and 5,787 controls) with 9,654 ESCC cases and 10,058 controls for follow-up. In a logistic regression model adjusted for age, sex, study and two eigenvectors, two new loci achieved genome-wide significance, marked by rs7447927 at 5q31.2 (per-allele odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.82-0.88; P = 7.72 × 10-20) and rs1642764 at 17p13.1 (per-allele OR = 0.88, 95% CI = 0.85-0.91; P = 3.10 × 10-13). rs7447927 is a synonymous SNP in TMEM173, and rs1642764 is an intronic SNP in ATP1B2, near TP53. Furthermore, a locus in the HLA class II region at 6p21.32 (rs35597309) achieved genome-wide significance in the two populations at highest risk for ESSC (OR = 1.33, 95% CI = 1.22-1.46; P = 1.99 × 10-10). Our joint analysis identifies new ESCC susceptibility loci overall as well as a new locus unique to the population in the Taihang Mountain region at high risk of ESCC. © 2014 Nature America, Inc. All rights reserved. Source

Discover hidden collaborations